Therefore, the present studies were a pre-clinical evaluation of the efficacy of SFN as an adjuvant to DOX chemotherapy, and a comparison of its effects on Nrf2 activity in cancer cells and primary cardiomyocytes. Here, NFE2L2 is linked to cancer.